FDA approves TREMFYA label expansion

Phanes Therapeutics reports updated Phase 2 results for spevatamig (PT886) in combination with chemotherapy

GSK reports positive phase III data for bepirovirsen in chronic hepatitis B

Sanofi's venglustat receives FDA priority review for type 3 Gaucher disease

Antengene receives Chinese clearance for Phase III study of ATG-022 in CLDN18.2+ advanced gastric/GEJ cancer

Ribo submits Phase 2 trial application for RBD1119 to European regulator

US FDA extends review timeline for AstraZeneca's camizestrant application

Circio and AaviGen partner to develop next-generation gene therapies for heart disease

CordenPharma acquires AmbioPharm, expanding peptide API capacity

OncoZenge secures European approval for Phase III BEAM-Pain trial of BupiZenge

AstraZeneca's Enhertu recommended for EU approval in HER2-positive solid tumours

Lundbeck's Vyepti (eptinezumab) receives South Korean approval for preventive treatment of migraine

Eli Lilly reports positive Phase 1b results for VERVE-102

Pierre Fabre Laboratories' BRAFTOVI (encorafenib) combination receives CHMP positive opinion in BRAFV600E-mutant mCRC

Menarini Group to present new elacestrant and tagraxofusp data at ASCO 2026 Annual Meeting